Intellia Therapeutics, Inc. (NTLA) is a cutting-edge biotechnology company engaged in developing a revolutionary class of potential treatments aimed at addressing diseases with high unmet need. The company is focused on the development and commercialization of pioneering genome editing therapies using the CRISPR/Cas9 system.
Founded in 2014, Intellia is headquartered in Cambridge, Massachusetts, in the hub of the U.S. biotechnology industry. The company’s team consists of industry veterans, leading scientists, researchers, and professionals dedicated to transforming the lives of patients living with severe and life-threatening diseases.
At the core of their operations is the powerful gene-editing technology known as CRISPR/Cas9. This not only helps to modify disease-causing genes but also holds the potential of providing definitive, curative therapies to patients with genetic diseases. By harnessing the powerful capabilities of the CRISPR/Cas9 system, Intellia aims to develop treatments that can permanently eliminate diseases from a patient’s body, representing a quantum leap forward in the medical treatment of genetic diseases.
A key differentiator for Intellia lies in their strategic alliances with major pharmaceutical companies including Novartis and Regeneron. These partnerships help to accelerate the development and commercialization of their revolutionary gene-editing treatments.
The company's pipeline encompasses various programs for the treatment of rare genetic disorders such as transthyretin amyloidosis (ATTR) and hereditary angioedema, as well as several others including haemophilia A & B and sickle cell disease. Furthermore, Intellia also focuses on treating cancer through the development of cellular therapies.
Intellia is not only at the forefront of gene-editing therapies but is also on the cutting edge of the regulatory landscape. As a pioneer in the clinical application of CRISPR/Cas9, the company is working closely with regulatory authorities to both define and navigate this emerging field.
Proud of its progressive patient-centric approach, Intellia Therapeutics puts the patient at the forefront of everything they do. They align their goals with those of the patients they serve – to get safe, efficacious, and curative therapies to patients as quickly as possible. While its ambitions are grand, Intellia’s commitment is simple - to use its groundbreaking technology to make a real difference in people’s lives.
To date, Intellia Therapeutics, Inc., trading on the NASDAQ Stock Exchange with ticker NTLA, has established itself as a leader in the promising field of gene editing, moving one step closer to providing patients around the world with life-changing therapies.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Intellia Therapeutics (NTLA) saw its short interest rise to 41.97% of the float on September 15th, an increase of 6.27% from August 31st, indicating growing bearish sentiment. Hedge funds showed mixed activity, with 187 institutional investors increasing their positions and 143 decreasing them, while company insiders made five sales and zero purchases in the last six months. Analysts have provided varying price targets for NTLA, with a median target of $17.0.
Intellia Therapeutics has received Priority Review status from the FDA for its gene editing therapy, lonvo-z, for hereditary angioedema, signaling regulatory comfort and accelerating its path to commercialization. This development is expected to significantly impact the company's revenue mix and operating costs, moving it closer to profitability. While the Priority Review strengthens the investment narrative by focusing on a near-term regulatory outcome and extends the cash runway into 2027, potential risks include payer pushback, competition, and the challenge of scaling a one-time treatment.
Intellia Therapeutics received FDA Priority Review for its Biologics License Application for lonvo-z, a gene-editing therapy for hereditary angioedema. This positions lonvo-z as a potential first in vivo CRISPR-based therapy in the U.S. and supports Intellia's strategy for earlier commercialization and revenue growth, although it also highlights concentration risk on the success of this single product.
Intellia Therapeutics (NTLA) stock recently jumped after the FDA accepted its Biologics License Application for lonvo-z, a CRISPR-based hereditary angioedema therapy, and granted it Priority Review. Despite a 6.7% gain in one day and a 33.12% year-to-date return, the stock is considered significantly undervalued by Simply Wall St's fair value estimate of $23.94 against its current trading price of $12.26. However, its high P/S ratio of 28.9x, compared to peers and the US Biotech average, suggests potential valuation risk if revenue forecasts cool.
The US FDA has accepted Intellia Therapeutics’ application for lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR-Cas therapy, and granted it priority review. A phase 3 trial showed a single dose reduced hereditary angioedema attacks by 87% compared to placebo. If approved, lonvo-z could be the first authorized in vivo CRISPR-Cas therapy and a one-time treatment for hereditary angioedema.
Intellia Therapeutics shares rose 8% after the FDA granted Priority Review to its Biologics License Application for lonvo-z, a potential one-time CRISPR-based therapy for hereditary angioedema (HAE). The FDA set a target action date of March 10, 2027, for the drug, which demonstrated an 87% reduction in HAE attacks in its Phase 3 trial. This marks a significant step towards potentially introducing the world's first in vivo CRISPR-based treatment.
Intellia Therapeutics has secured a $400 million senior secured credit facility with OrbiMed to fund its global pivotal Phase 3 HAELO trial for NTLA-2002 (lonvo-z), a single-dose CRISPR therapy for hereditary angioedema. This financing strategy allows Intellia to fund the trial without immediately diluting shareholders, with the loan structured against future revenue or royalty streams. The move underscores the growing trend of CRISPR-based medicines moving into pivotal development and places emphasis on the HAELO trial's success and enrollment pace.